8th Jun 2023 15:30
Renalytix plc
("Renalytix" or the "Company")
Result of General Meeting
LONDON and SALT LAKE CITY, June 8, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that at the General Meeting ("GM") held earlier today all resolutions were passed. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 11 May 2023.
The results of the GM are detailed below:
Resolution | In Favour Votes | % |
| Against Votes | % |
| Withheld Votes |
1 | 35,540,650 | 98.8% |
| 439,984 | 1.2% |
| 62,458 |
2 | 35,509,132 | 98.7% |
| 471,662 | 1.3% |
| 62,298 |
For further information, please contact:
Renalytix plc | www.renalytix.com |
James McCullough, CEO | Via Walbrook PR |
| |
Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 |
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea |
|
| |
Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 |
Gary Clarence / Shalin Bhamra |
|
Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] |
Paul McManus / Alice Woodings / Lianne Applegarth | Mob: 07980 541 893 / 07407 804 654 / 07584 391 303 |
CapComm Partners | |
Peter DeNardo
| Tel: 415-389-6400 or [email protected] |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
Related Shares:
Renalytix Plc